GOTHENBURG, SE / ACCESS Newswire / April 24, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)
First quarter 2026 (Jan-Mar)
Net sales amounted to SEK 241.0 million (218.6), corresponding to growth of 10 percent in SEK.
Organic growth was 23 percent in local currencies. Excluding revenue from heart trials the organic growth was 18 percent in local currencies.
Thoracic sales increased by 27 percent in local currencies and by 19 percent excluding revenue from heart trials.
Abdominal sales increased by 24 percent in local currencies.
Services sales decreased by -10 percent.
Total gross margin was 71 percent (73).
Operating income (EBIT) amounted to SEK 31.9 million (26.6).
Operating income before depreciation and amortization (EBITDA) amounted to SEK 51.1 million (43.0), corresponding to an EBITDA margin of 21 percent (20). The underlying EBITDA margin was 24 percent, excluding costs related to US heart go-to-market preparations.
Net profit amounted to SEK 36.3 million (-12.4), impacted by currency effects in cash and cash equivalents of SEK 8.5 million (-22.5).
Earnings per share amounted to SEK 1.15 (-0.39).
Cash flow from operating activities was SEK 65.3 million (-15.3), primarily impacted by an increase in sales. Total cash flow amounted to SEK 7.6 million (-77.2), impacted by investments in R&D projects of SEK -43.0 million.
Significant events in the quarter
Management change at XVIVO - CFO transitions to new role
Events after the end of the period
Preliminary one-year follow-up data from the US PRESERVE heart preservation trial was presented at ISHLT. The trial met its pre-specified primary endpoints.
Results from first clinical trial using hypothermic oxygenated perfusion (HOPE) in direct procurement DCD heart transplantation was presented at ISHLT. The trial met its pre-specified primary endpoint.
One-year follow-up results from XVIVO's European multicenter heart trial published in the European Heart Journal.
CEO-comment
"Net sales for the first quarter amounted to SEK 241 million, reflecting a strong start to the year. In addition, for the second consecutive quarter we delivered positive total cash flow. Overall, the first quarter of the year was characterized by high activity, both commercially and clinically, as well as strong scientific momentum in both heart and lung, reinforced by the presentations at ISHLT in the beginning of the second quarter. We remain committed to our growth journey and continue to take important steps toward fulfilling our vision that nobody should die waiting for a new organ." - Christoffer Rosenblad, CEO
For further information, please contact:
Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
Conference Call
Christoffer Rosenblad, CEO and Kristoffer Nordström, CFO, will present the report in a conference call today at 2.00 PM CET / 8.00 AM EST. For registration to the conference call, see information in previous press release: https://investor.xvivogroup.com/press-release?slug=conference-call-on-interim-report-january-march-2026
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-04-24 07:30 CEST.
Attachments
XVIVO Interim Report Q1 2026
SOURCE: XVIVO Perfusion AB
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/interim-report-january-march-2026-1160890
